dc.contributor.advisor | Schanz, Julie PD Dr. | |
dc.contributor.author | Rothmann, Bärbel Christa Elfriede | |
dc.date.accessioned | 2020-01-03T11:06:51Z | |
dc.date.available | 2020-01-22T23:50:03Z | |
dc.date.issued | 2020-01-03 | |
dc.identifier.uri | http://hdl.handle.net/21.11130/00-1735-0000-0005-12E2-7 | |
dc.identifier.uri | http://dx.doi.org/10.53846/goediss-7792 | |
dc.language.iso | deu | de |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject.ddc | 610 | de |
dc.title | Prognostische Bedeutung seltener Einzelchromosomenanomalien bei myelodysplastischen Syndromen | de |
dc.type | doctoralThesis | de |
dc.title.translated | Prognostic impact of rare single chromosomatic anomalities at myelodysplastic syndroms | de |
dc.contributor.referee | Hahn, Heidi Eva Prof. Dr. | |
dc.date.examination | 2020-01-15 | |
dc.description.abstracteng | Cytogenetic in myelodysplastic syndromes offer a valid prognostic factor for OS and AML free survival in the IPSS-R. For roughly 90% of cytogenetic abnormalities the prognostic impact is already known. This analysis therefore deals with some of these rare single abnormalities within the remaining 10%. More than 7000 cases where screened. Core results refer to the del(13q) and balanced translocations with a significantly better survival rate and to abnormalities at chromosomes 20 (without del (20q)) and patients with monosomie 9 which have a significantly shorter overall survival rate. For monosomie 9 patients and such with chromosome 20 abnormalities this applies for the AML free survival as well. | de |
dc.contributor.coReferee | Schön, Margarete Prof. Dr. | |
dc.subject.eng | myelodysplastic syndrom | de |
dc.subject.eng | rare single chromosomic abnormalities | de |
dc.identifier.urn | urn:nbn:de:gbv:7-21.11130/00-1735-0000-0005-12E2-7-2 | |
dc.affiliation.institute | Medizinische Fakultät | de |
dc.subject.gokfull | Medizin (PPN619874732) | de |
dc.description.embargoed | 2020-01-22 | |
dc.identifier.ppn | 1686426933 | |